A constitutively active mutant beta 2-adrenergic receptor is constitutively desensitized and phosphorylated.
about
The melanosomal/lysosomal protein OA1 has properties of a G protein-coupled receptorLigand-induced desensitization of the human CXC chemokine receptor-2 is modulated by multiple serine residues in the carboxyl-terminal domain of the receptorThe chemokine receptor CCR1 is constitutively active, which leads to G protein-independent, β-arrestin-mediated internalizationEnhanced spontaneous activity of the mu opioid receptor by cysteine mutations: characterization of a tool for inverse agonist screeningDetection of receptor ligands by monitoring selective stabilization of a Renilla luciferase-tagged, constitutively active mutant, G-protein-coupled receptorRearrangement of a polar core provides a conserved mechanism for constitutive activation of class B G protein-coupled receptorsConstitutively active CCR5 chemokine receptors differ in mediating HIV envelope-dependent fusion.Rapid desensitization of the TRH receptor and persistent desensitization of its constitutively active mutant.Ligand-induced overexpression of a constitutively active beta2-adrenergic receptor: pharmacological creation of a phenotype in transgenic mice.Multiple ligand-specific conformations of the β2-adrenergic receptorInhibition of constitutive signaling of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor by protein kinases in mammalian cells in cultureConstitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics.Insight into the mechanism of dopamine D1-like receptor activation. Evidence for a molecular interplay between the third extracellular loop and the cytoplasmic tail.Phosphorylation of the platelet-derived growth factor receptor-beta and epidermal growth factor receptor by G protein-coupled receptor kinase-2. Mechanisms for selectivity of desensitization.Constitutive Desensitization of Opioid Receptors in Peripheral Sensory Neurons.Inverse agonist exposure enhances ligand binding and G protein activation of the human MT1 melatonin receptor, but leads to receptor down-regulation.Regulated and constitutive activation of specific signalling pathways by the human S1P5 receptor.Constitutive internalization of constitutively active agiotensin II AT(1A) receptor mutants is blocked by inverse agonists.Expression of beta-arrestins in toxic and cold thyroid nodules.G protein-coupled receptor kinase-mediated desensitization of metabotropic glutamate receptor 1A protects against cell death.Spontaneous human B2 bradykinin receptor activity determines the action of partial agonists as agonists or inverse agonists. Effect of basal desensitization.Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses.The conformational change responsible for AT1 receptor activation is dependent upon two juxtaposed asparagine residues on transmembrane helices III and VII.A constitutively active mutant of the alpha 1B-adrenergic receptor can cause greater agonist-dependent down-regulation of the G-proteins G9 alpha and G11 alpha than the wild-type receptor.Binding of low affinity N-formyl peptide receptors to G protein. Characterization of a novel inactive receptor intermediate.Activating and inactivating mutations in N- and C-terminal i3 loop junctions of muscarinic acetylcholine Hm1 receptors.Modulation of histamine H(2) receptor signalling by G-protein-coupled receptor kinase 2 and 3Beta-agonist-induced constitutive beta(2)-adrenergic receptor activity in bovine tracheal smooth muscle.Agonist-induced phosphorylation of the angiotensin II (AT(1A)) receptor requires generation of a conformation that is distinct from the inositol phosphate-signaling state.Functional characterization of five constitutively activating thyrotrophin receptor mutations.The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation.Breaking the integrin hinge. A defined structural constraint regulates integrin signaling.Differential conformational requirements for activation of G proteins and the regulatory proteins arrestin and G protein-coupled receptor kinase in the G protein-coupled receptor for parathyroid hormone (PTH)/PTH-related protein.A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists.Phosphorylation-induced conformation of β2-adrenoceptor related to arrestin recruitment revealed by NMR.Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo.Cannabinoid Receptor-2 Ameliorates Inflammation in Murine Model of Crohn's Disease.Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity
P2860
Q24306837-0C06B480-A195-4DCD-8854-19AB30DD86FEQ24310201-EF00A772-2EA1-4C77-BC56-9B5D51DB2CB7Q24337078-FF13CDA4-BB33-4027-9DFD-492710C20192Q24804972-3E3831BD-7185-4539-A1DB-E65F03848282Q28364896-670844E6-1B9D-4AB7-A647-65FB1B0292C1Q33806122-184DCC55-A48B-4084-ABCD-86C35E9EE3CCQ34565057-8224FD25-C750-479D-9357-787C3743B413Q35042241-2A747BA3-8690-40A1-B855-51FD83DFAF0DQ35902964-C79E248B-3B9A-45AD-8EC1-4C9ABE3EC16BQ36115098-7AC4958B-DFA8-40CF-BF71-3860883D5C7BQ36400438-6CC3B102-C119-4518-AD4B-DFAFFF26947EQ37157903-1774F04E-E9B1-414A-816D-EEA52BDAFE35Q38359032-56E9E8A8-B307-4723-8734-5581451989FEQ38361904-619638A1-8E60-44C3-9969-8BFEC3987993Q39359627-C122EEEA-427F-4D0C-BD46-0A1B771A9A9EQ40084721-4E5F8E78-0E69-43ED-B6E8-2BEF54A099E9Q40672751-3B5395D5-4936-4090-9DA4-251F9B5A8C2BQ40765666-25164F95-0C96-41EF-9BB4-8EFC8DDB5FCAQ40837011-D1BF235C-FA11-4DD9-9778-5F191C69E9BAQ40855666-FF2CF360-80E5-4DD3-A3D7-E632FBDA9D4DQ40924435-E431FFF5-F5DD-43F8-A8F8-D3AB7CFDA82BQ40943005-507B1463-7CBC-4C2C-9B51-CB9DB9656C21Q41127850-3FCFC102-2FFC-4C05-A400-8B964A83D7D0Q41150875-D9FE11B7-E230-4AB7-84DC-4085289B4DDDQ41346960-67E3AF2A-539F-4F33-8134-96247EF64880Q41357756-BA9269A7-D962-44B6-9EA9-BE2983E2BD4CQ41899485-07802E8C-A24F-413D-B231-3DB0CF9CE808Q42262098-81BE9A8A-DDC6-40E7-81D4-B807B2260053Q42482690-3A9B94E1-CB39-4159-9B2C-83225C430534Q42494012-C353864F-C78E-40CF-8714-BA6FF6BB2CA7Q42521824-8B41B0C3-CD32-40DB-BF2E-2FEF4F0A606DQ43482152-C0DA5714-6C29-4F3E-A068-7DD59F134166Q43626694-7507F819-06D7-475F-AE1A-A9E56AA00202Q43940109-18AE5FC2-B869-414F-B4C6-3009B1186CB1Q48240503-D567A37D-82A2-4B7C-AF36-9D1DE293E04BQ48903035-685D82DE-3134-4EFB-AFD9-50BF2FA0D806Q49579501-5E241A41-2BFE-4F3B-BE33-360BE71561AAQ58798205-73250039-A7D6-4E68-9685-175413EC573B
P2860
A constitutively active mutant beta 2-adrenergic receptor is constitutively desensitized and phosphorylated.
description
1994 nî lūn-bûn
@nan
1994 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի մարտին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
A constitutively active mutant ...... sensitized and phosphorylated.
@ast
A constitutively active mutant ...... sensitized and phosphorylated.
@en
type
label
A constitutively active mutant ...... sensitized and phosphorylated.
@ast
A constitutively active mutant ...... sensitized and phosphorylated.
@en
prefLabel
A constitutively active mutant ...... sensitized and phosphorylated.
@ast
A constitutively active mutant ...... sensitized and phosphorylated.
@en
P2093
P2860
P356
P1476
A constitutively active mutant ...... sensitized and phosphorylated.
@en
P2093
P2860
P304
P356
10.1073/PNAS.91.7.2699
P407
P577
1994-03-01T00:00:00Z